These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2090306)

  • 1. Polymers to treat brain tumours.
    Brem H
    Biomaterials; 1990 Nov; 11(9):699-701. PubMed ID: 2090306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
    Brem H; Piantadosi S; Burger PC; Walker M; Selker R; Vick NA; Black K; Sisti M; Brem S; Mohr G
    Lancet; 1995 Apr; 345(8956):1008-12. PubMed ID: 7723496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable polymers for drug delivery to the brain.
    Langer R
    ASAIO Trans; 1988; 34(4):945-6. PubMed ID: 2851308
    [No Abstract]   [Full Text] [Related]  

  • 4. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
    Brem H; Tamargo RJ; Olivi A; Pinn M; Weingart JD; Wharam M; Epstein JI
    J Neurosurg; 1994 Feb; 80(2):283-90. PubMed ID: 8283268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy.
    Wu MP; Tamada JA; Brem H; Langer R
    J Biomed Mater Res; 1994 Mar; 28(3):387-95. PubMed ID: 8077254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
    Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H
    Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
    Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
    Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers.
    Grossman SA; Reinhard C; Colvin OM; Chasin M; Brundrett R; Tamargo RJ; Brem H
    J Neurosurg; 1992 Apr; 76(4):640-7. PubMed ID: 1545259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of the carmustine implant.
    Fleming AB; Saltzman WM
    Clin Pharmacokinet; 2002; 41(6):403-19. PubMed ID: 12074689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
    Judy KD; Olivi A; Buahin KG; Domb A; Epstein JI; Colvin OM; Brem H
    J Neurosurg; 1995 Mar; 82(3):481-6. PubMed ID: 7861228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants.
    Strasser JF; Fung LK; Eller S; Grossman SA; Saltzman WM
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1647-55. PubMed ID: 8531140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
    Yuan X; Dillehay LE; Williams JR; Williams JA
    Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain.
    Brem H; Kader A; Epstein JI; Tamargo RJ; Domb A; Langer R; Leong KW
    Sel Cancer Ther; 1989; 5(2):55-65. PubMed ID: 2772427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustainable release of carmustine from biodegradable poly[((D,L))-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies.
    Tseng YY; Liao JY; Chen WA; Kao YC; Liu SJ
    Expert Opin Drug Deliv; 2013 Jul; 10(7):879-88. PubMed ID: 23289446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic, implantable, biodegradable polymers for controlled release of radiosensitizers.
    Yuan X; Fahlman C; Tabassi K; Williams JA
    Cancer Biother Radiopharm; 1999 Jun; 14(3):177-86. PubMed ID: 10850302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gliadel wafers for treatment of brain tumors.
    Med Lett Drugs Ther; 1998 Sep; 40(1035):92. PubMed ID: 9760950
    [No Abstract]   [Full Text] [Related]  

  • 17. Brain biocompatibility of a biodegradable, controlled-release polymer in rats.
    Tamargo RJ; Epstein JI; Reinhard CS; Chasin M; Brem H
    J Biomed Mater Res; 1989 Feb; 23(2):253-66. PubMed ID: 2708412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma.
    Williams JA; Yuan X; Dillehay LE; Shastri VR; Brem H; Williams JR
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):631-9. PubMed ID: 9806525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
    Olivi A; Grossman SA; Tatter S; Barker F; Judy K; Olsen J; Bruce J; Hilt D; Fisher J; Piantadosi S;
    J Clin Oncol; 2003 May; 21(9):1845-9. PubMed ID: 12721262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
    Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
    Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.